Presented at #ERA26: In this 104-week trial involving patients with primary membranous nephropathy, the type II anti-CD20 antibody obinutuzumab was superior to the calcineurin inhibitor tacrolimus in inducing complete remission. Full phase 3 MAJESTY trial results: nej.md/4dZsVPD @ERAkidney

Amazing event not to miss! Zoom link in the invite @onconephsociety

Tweetorial on Histotripsy related AKI @renalmyeloma @HofstraKidney 1) What is histotripsy? Histotripsy is a non-invasive, FDA-approved (as of late 2023) cancer treatment that uses focused ultrasound waves to destroy liver tumors without incisions, radiation, or chemotherapy.pmc.ncbi.nlm.nih.gov/article… @onconephsociety

Finally out in @AGA_CGH! 📝 Our HK population-based observational study demonstrated a lower 2-year risk of complicated #UGIB in apixaban users compared to edoxaban (NNH 244) and rivaroxaban (NNH 427). 🚨 cghjournal.org/article/S1542…

Pls join us on @onconephsociety educational series on one of the hot topics “ T cell mediated therapies in MM and Amyloidosis” 🛑April 24th 2026 12 pm EDT Presented by Dr Nadia Al Haddad and Dr David Ortiz-Melo

What we know about the current perspectives of using bispecific antibodies in Glomerular Diseases @kdjhaveri @asnpublications

Single-center perspective of glomerular pathology in checkpoint inhibitor-treated patients @Arjun_Mohan1 @MPAlexanderMD @HerrmannMd @KIReports kireports.org/article/S2468-…

Pls join us for an amazing conference on Multiple Myeloma and Kidney Transplantation:Best Practices, Challenges and Future Directions ✅ March 20th 2026, 12PM EST @itunuowoyemi ✅Dr. Owoyemi and Dr. Ziolkowski

For the first time @ISNWCN is organizing an onconephrology not to be missed with outstanding global speakers #ISNWCN privileged to have as co-chairs of this course @kdjhaveri @PepaSolerR

🌟🌟Upcoming is a great session on Diagnosing and managing ICI nephrotoxicity and GFR Assessment in patients with cancer - Insights from ASON position statements 💥ISN-ASON joint webinar 💥November 18th 1 pm CET @PAmarapurkar @HerrmannMd @onconeph @ISNkidneycare

🎥Watch Dr Daniel Tak Mao Chan present the NDT publication: Chronic Kidney Disease G3-5 in Lupus Nephritis- Prevalence, Progression, and Risk Factors oup.cloud.panopto.eu/Panopto…

KDIGO is excited to share the publication of the 2025 Clinical Practice Guideline for the Management of IgA Nephropathy (#IgAN) and IgA Vasculitis (#IgAV), along with the Executive Summary in @Kidney_Int. Read the Guideline in KI: kdigo.co/KDIGO-IgAN-IgAV-Gui… Download the Executive Summary: kdigo.co/IgAN-IgAV-Guideline… Read the News Release: kdigo.co/KDIGO-IgAN-IgAV-Gui… Co-chaired by Dr. Jürgen Floege (DE) and @BradRovin, this update to the 2021 KDIGO Glomerular Diseases Guideline on IgAN incorporates evidence through August 2024. Given the rapid pace of discovery, KDIGO will continue to update the guideline regularly so clinicians and patients have access to the latest science and recommendations. “This guideline represents a fundamental shift in how we approach IgA nephropathy,” said Dr. Floege. “For the first time, we can target both the immune mechanisms driving IgA injury and the kidney’s maladaptive responses. This dual strategy offers a roadmap to slow progression and extend kidney survival in ways not possible just a few years ago.” “The science is moving faster than ever, and the treatment landscape has changed dramatically,” said Dr. Rovin. “With therapies like targeted-release budesonide, sparsentan, and SGLT2 inhibitors, we can intervene earlier and tailor care. We are moving from a single approach to a toolkit of therapies that can truly change outcomes for people around the world." Download the Guideline: kdigo.co/KDIGO-IgAN-IgAV-Gui…

The latest 2025 #Hypertension Guidelines are out 📣 #Nephpearls 📌 Use of risk-based thresholds for initiation of BP treatment 📌 BP thresholds and recommendations for treatment and follow-up 📌 Screening for features suggesting secondary hypertension 👉🏼 pubmed.ncbi.nlm.nih.gov/4081…

The Mayo MGRS Prediction Tool calculates the risk of finding monoclonal gammopathy of renal significance in a kidney biopsy in patients with monoclonal gammopathy - Kidney International @basmeomeo ⁦@fervenzafernan1⁩ ⁦@SethiRenalPath⁩ kidney-international.org/art…

American Society of Onconephrology Educational Series presents a seminar on “Updates on the Pathology of MGRS lesions” by Professor Samih Nasr moderated by Dr. Chintan Shah 🌟May 23, 12 PM EST 🌟Don’t miss the great opportunity !

Most viewed this week from @JAMAOnc: Prophylactic IV magnesium administration was associated with a lower risk of cisplatin-associated acute kidney injury (CP-AKI) in patients with cancer undergoing cisplatin chemotherapy. ja.ma/44fFHqa

New "X"orial alert 1/ What medications, if any, do you give to prevent cisplatin-associated acute kidney injury (CP-AKI )? A new paper in @JAMAOnc led by @ShrutiGkidney and @DavidLeaf9 found that IV magnesium may reduce the risk of CP-AKI. Here’s a brief #tweetorial jamanetwork.com/journals/jam… @JAMA_current

For the kidney month of March, American Society of Onconephrology would like to increase awareness of the kidney disease and electrolyte abnormalities. ✅Please check on your kidneys with your doctor

This article provides a comprehensive review of MTX metabolism, mechanisms and prevention of MTX-AKI, and its management. bit.ly/KID0725

Light-chain (AL) amyloidosis for nephrologists—treatment standard doi.org/10.1093/ndt/gfae224